Sector News

Intrexon to buy floundering GenVec for gene delivery tech

January 25, 2017
Life sciences

Intrexon is set to buy GenVec in an all-stock deal to add a gene delivery platform to its arsenal. The goal is to pair the technology with Intrexon’s existing capabilities to create viral delivery vectors with significantly greater payload capacities.

Germantown, Maryland-based Intrexon has agreed to pay $7 a share for its Gaithersburg, Maryland-based neighbor, a price approximately 50% higher than that GenVec was trading at prior to news of the deal. Intrexon will also give GenVec shareholders half of any milestones and royalties that result from the latter’s pact with Novartis over the next three years.

In return for the outlay, Intrexon has secured AdenoVerse, a platform of adenovirus vectors for use in gene delivery for therapeutics and vaccines. Intrexon plans to pair the platform with its existing suite of technologies.

“Intrexon’s proficiency in using various viral as well as non-viral transfer techniques to integrate our gene programs affords us the capability to pursue an array of in vivo and ex vivo gene and cell therapy approaches, and the addition of a helper-dependent adenoviral system with a substantial payload capacity dramatically expands the types of in vivo therapeutic programs we can pursue,” Intrexon CSO Thomas Reed said in a statement.

The goal is to enable adenoviral delivery of payloads of 30kb or more. Adenoviruses typically have a packaging capacity of 7-8kb, as do retroviruses. Researchers have worked for years to increase the payloads of viral vectors so they can carry multiple genes and native transcriptional regulatory elements. Intrexon thinks it can succeed where others have struggled by pairing the technologies.

Given that GenVec’s market cap clocked in at $13.6 million following a post-deal-announcement bump, Intrexon—a company with a $2.4 billion market cap and a billionaire CEO—is risking little to test out its hunch.

GenVec was a gene delivery pioneer but never fully recovered from the phase 3 failure of its pancreatic cancer candidate in 2010. That wiped a chunk off the company’s stock price, which had already fallen considerably from the IPO value it secured at a time when the dot-com bubble was starting to cause chaos on Nasdaq.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach